Published online before print January 14, 2008, doi: 10.1161/CIRCULATIONAHA.107.698514
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:526-535.)
© 2008 American Heart Association, Inc.
Heart Failure |
Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia
From Wayne State University, Detroit, Mich (J.K.G.); Veterans Administration Medical Center and University of Minnesota, Minneapolis (I.S.A.); Ohio State University, Columbus (W.T.A.); University of California at Los Angeles, Division of Cardiology (G.C.F); University of California at San Diego (B.G.); Monash University, Melbourne, Australia (H.K.); University of California at San Francisco (B.M.M.); Amgen Inc, Thousand Oaks, Calif (S.M.W., M-L.T., Y.S., B.K.); and University of Alberta, Edmonton, Alberta, Canada (P.A.).
Correspondence to Jalal K. Ghali, MD, University Health Center, 4201 St Antoine, 2E, Detroit, MI 48201. E-mail jghali{at}med.wayne.edu
Received March 6, 2007; accepted November 9, 2007.
Background— Substantial evidence suggests that anemia is an independent risk factor for worse outcomes in patients with heart failure (HF). The Study of Anemia in Heart Failure Trial (STAMINA-HeFT) is the largest multicenter, randomized, double-blind, placebo-controlled trial to date evaluating the effect of treating anemia in HF.
Methods and Results— Patients (N=319) with symptomatic HF, left ventricular ejection fraction 
40%, and hemoglobin 
9.0 g/dL and 12.5 g/dL were randomized (double-blind) to placebo (N=157) or darbepoetin alfa (N=162) subcutaneously every 2 weeks for 1 year (target hemoglobin, 14.0±1.0 g/dL). The primary end point was change from baseline to week 27 in treadmill exercise time. Secondary end points were change from baseline in New York Heart Association class and quality of life at week 27. An additional prespecified efficacy analysis included the time to death by any cause or first HF-related hospitalization by 1 year. At baseline, the median (interquartile range) hemoglobin was 11.4 (10.9, 12.0) g/dL. At week 27, darbepoetin alfa treatment increased median (interquartile range) hemoglobin by 1.8 (1.1, 2.5) g/dL (placebo, 0.3 [–0.2, 1.0] g/dL; P<0.001). Of the patients treated with darbepoetin alfa, 85% achieved 2 consecutive hemoglobin levels of 14.0±1.0 g/dL during the study and experienced a hemoglobin increase of 1.0 g/dL from baseline. By intent-to-treat analysis, darbepoetin alfa treatment did not significantly improve exercise duration, New York Heart Association class, or quality of life score compared with placebo. A nonsignificant trend was observed toward a lower risk of all-cause mortality or first HF hospitalization in darbepoetin alfa–treated patients compared with placebo (hazard ratio, 0.68; 95% CI, 0.43, 1.08; P=0.10). Occurrences of adverse events were similar in both treatment groups.
Conclusions— In this study of patients with symptomatic HF and anemia, treatment with darbepoetin alfa was not associated with significant clinical benefits. Darbepoetin alfa treatment was well tolerated and effectively raised hemoglobin. A trend of lower risk of morbidity and mortality was observed.
CLINICAL PERSPECTIVE
Related Article:
-
Clinical Summaries
Circulation 2008 117: 453-455.[Full Text]
This article has been cited by other articles:
 |
|
 |
|
  Anemia Treatment in Patients with Symptomatic Heart Failure Journal Watch Cardiology, February 6, 2008; 2008(206): 4 - 4. [Full Text]
|
|